Cytotoxic Activity of CD4+ T Cells against Autologous Tumor Cells
Open Access
- 1 September 1995
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 86 (9) , 854-860
- https://doi.org/10.1111/j.1349-7006.1995.tb03096.x
Abstract
The 51Cr‐release assay is mostly applied to detecting the cytotoxic activity of CD8+ T cells, and little is known about the activity of CD4+ T cells. Therefore, the correlation between the cytotoxic activity of CD4+ or CD8+ T cells and the incubation period with autologous tumor cells was analyzed by two methods. The incubation periods were 4 and 20 h (4 h and 20 h assay) for the 51Cr‐release assay. Eight pairs of tumor cells and T cells were assayed. T cells were fractionated into CD4+ and CD8+ T cells by using magnetic beads and panning methods, and those cells were activated by culture with recombinant interleukin‐2 and immobilized anti‐CD3 monoclonal antibody. In 6 out of 8 cases, no cytotoxic activity of CD4+ T cells was detected by the 4 h assay, whereas cytotoxic activity was detected in all cases in the 20 h assay. The cytotoxic activities in 20 h assay of CD4+ T cells were increased 67‐fold in comparison with the activities in 4 h assay (range: 5–197). In the case of CD8+ T cells, cytotoxic activities were detected in 6 out of 8 cases in the 4 h assay. The lytic unit ratio of CD4+ and CD8+ T cells was calculated as 1.5 in the 20 h assay (range: 0.2‐>7.2) versus 0.4 in the 4 h assay (range: < 0.1–1.3). Cytotoxic activities in colorimetric assay using Crystal Violet with a 24 h incubation were similar to those in the 20 h 51Cr‐release assay in all eight cases. These results indicate that CD4+ T cells have cytotoxic activity as strong as that of CD8+ T cells towards autologous tumor cells.Keywords
This publication has 34 references indexed in Scilit:
- Rapid separation of CD4+ and CD19+ lymphocyte populations from human peripheral blood by a magnetic activated cell sorter (MACS)Cytometry, 1993
- Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinomaThe Lancet, 1990
- TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCERThe Lancet, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.The Journal of Experimental Medicine, 1988
- Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.The Journal of Experimental Medicine, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusionsInternational Journal of Cancer, 1983
- Clonal analysis of cytotoxic T cell response against human melanoma.The Journal of Experimental Medicine, 1983
- Characteristics of human large granular lymphocytes and relationship to natural killer and K cellsThe Journal of Experimental Medicine, 1981